Spinal Muscular Atrophy Pipeline Summary

DelveInsight’s, “Spinal Muscular Atrophy - Pipeline Insight, 2026” report provides comprehensive insights about 19+ companies and 20+ pipeline drugs in Spinal Muscular Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Spinal Muscular Atrophy: Understanding

Spinal Muscular Atrophy: Overview

Spinal muscular atrophy (SMA) is a rare inherited neuromuscular disorder characterized by progressive degeneration of the anterior horn cells (lower motor neurons) in the spinal cord, resulting in symmetrical proximal muscle weakness, muscle atrophy, and hypotonia. The disease is primarily caused by homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene on chromosome 5q13, which accounts for approximately 95% of cases. SMA exhibits a broad clinical spectrum, ranging from severe prenatal or infantile-onset forms associated with early mortality to milder adult-onset forms with relatively preserved life expectancy. It is one of the leading genetic causes of infant mortality and follows an autosomal recessive inheritance pattern.

The primary cause of SMA is the homozygous deletion or pathogenic mutation of the SMN1 gene, leading to inadequate production of the survival motor neuron (SMN) protein, which is essential for the maintenance and function of motor neurons. Because SMA is inherited in an autosomal recessive manner, affected individuals inherit one defective SMN1 allele from each parent. Disease severity is influenced by the number of copies of the SMN2 gene, a nearly identical gene that produces limited amounts of functional SMN protein. Individuals with more SMN2 copies generally exhibit milder disease phenotypes because the additional SMN protein partially compensates for the loss of SMN1 function.

SMA develops due to a deficiency of functional SMN protein resulting from SMN1 gene deletion or mutation. Although the exact mechanisms are not fully understood, SMN protein plays a crucial role in RNA processing, spliceosome assembly, mRNA transport within axons, cytoskeletal organization, and synaptic vesicle function. Reduced SMN protein disrupts these cellular processes, leading to selective degeneration of alpha motor neurons in the anterior horn of the spinal cord. Progressive motor neuron loss results in denervation of skeletal muscles, causing muscle weakness, atrophy, reduced muscle tone, and impaired motor function.

The diagnosis of SMA is primarily established through molecular genetic testing. Polymerase chain reaction (PCR) or multiplex ligation-dependent probe amplification (MLPA) is used to detect homozygous deletion of exon 7 in the SMN1 gene, offering high sensitivity and near-complete specificity. Determination of SMN2 copy number is routinely performed because it provides important prognostic information regarding disease severity. When initial genetic testing is inconclusive, additional investigations such as electromyography (EMG), nerve conduction studies, serum creatine kinase measurement, and, less commonly, muscle biopsy may be utilized to support the diagnosis and exclude alternative neuromuscular disorders.

The management of SMA has evolved substantially with the availability of disease-modifying therapies that increase functional SMN protein levels. Current approved therapies include nusinersen, an antisense oligonucleotide that enhances SMN2 exon 7 inclusion; onasemnogene abeparvovec, a gene replacement therapy delivering a functional copy of the SMN1 gene; and risdiplam, an orally administered small-molecule splicing modifier that promotes SMN protein production from SMN2. Alongside these therapies, comprehensive supportive care remains essential and includes respiratory support, nutritional management, physical and occupational therapy, orthopedic interventions for scoliosis and contractures, and multidisciplinary rehabilitation to optimize motor function, quality of life, and survival.

"Spinal Muscular Atrophy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spinal Muscular Atrophy pipeline landscape is provided which includes the disease overview and Spinal Muscular Atrophy treatment guidelines. The assessment part of the report embraces, in depth Spinal Muscular Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Muscular Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Muscular Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Spinal Muscular Atrophy.

Spinal Muscular Atrophy Emerging Drugs Chapters

This segment of the Spinal Muscular Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinal Muscular Atrophy Emerging Drugs

• Salanersen: Biogen

Salanersen is a novel, intrathecally administered antisense oligonucleotide (ASO) in development for SMA. Salanersen is designed to correct splicing of SMN2 pre-mRNA to increase production of SMN protein. It has a new chemistry that leads to high potency, enabling the potential for high efficacy with once-yearly dosing. In June 2026, Biogen Inc announced that the US Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA). Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Spinal Muscular Atrophy.

• GC101: GeneCradle Therapeutics

GC101 is an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional SMN1 (survival motor neuron 1) gene expression cassette to motor neurons using a recombinant AAV vector. Following intrathecal, intravenous, or intraventricular administration, the vector efficiently transduces the central nervous system, enabling sustained expression of the SMN protein in neurons. By restoring SMN protein levels, GC101 aims to improve motor neuron survival and function, thereby addressing the underlying genetic cause of SMA rather than only alleviating symptoms. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Spinal Muscular Atrophy.

• GB221: Gemma Biotherapeutics

GB221 is an investigational, next?generation gene therapy for SMA1 developed to express SMN1 in motor neurons. The absence of functional SMN1 protein in motor neurons is the underlying cause of SMA. GB221 is a one-time gene therapy that consists of an adeno?associated virus (AAV) human isolate, AAVhu68, encasing a functional copy of a codon?optimized SMN1 gene in a modified transgene expression cassette designed to reduce overexpression and sensory neurotoxicity. It is delivered directly to the cerebrospinal fluid (CSF) via intra-cisterna magna (ICM) injection. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Spinal Muscular Atrophy.

• ARV-027: Arvinas

ARV-027 is an investigational oral, peripherally restricted PROTAC degrader designed to selectively target and eliminate toxic polyglutamine-expanded androgen receptor (polyQ-AR) in skeletal muscle. PolyQ-AR is the root cause of motor dysfunction in spinal bulbar muscular atrophy (SBMA) or Kennedy’s disease due to the toxic gain of function imparted by the polyQ expansion on the AR. PolyQ-AR misfolds and aggregates in a ligand-dependent manner, disrupts normal transcription, and impairs muscle and mitochondrial function, ultimately driving progressive neuromuscular degeneration. . Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Spinal bulbar muscular atrophy.

Further product details are provided in the report……..

Spinal Muscular Atrophy: Therapeutic Assessment

This segment of the report provides insights about the different Spinal Muscular Atrophy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Spinal Muscular Atrophy

There are approx. 19+ key companies which are developing the therapies Spinal Muscular Atrophy. The companies which have their Spinal Muscular Atrophy drug candidates in the most advanced stage, i.e. Phase III include, Biogen and others.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinal Muscular Atrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal Muscular Atrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Muscular Atrophy drugs.

Spinal Muscular Atrophy Report Insights

• Spinal Muscular Atrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spinal Muscular Atrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Spinal Muscular Atrophy drugs?
• How many Spinal Muscular Atrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal Muscular Atrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spinal Muscular Atrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spinal Muscular Atrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Gemma Biotherapeutics
• Biogen
• GeneCradle Therapeutics
• Lantu Biopharma
• Argenx
• Scholar Rock
• Biocad
• NMD PHARMA A/S
• Arvinas
• AnnJi Pharmaceutical Co., Ltd.

Key Products

• GB221
• Salanersen
• GC101
• vesemnogene lantuparvovec
• Adimanebart
• Apitegromab
• ANB-004
• NMD670
• ARV-027
• AJ201